How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.
Pharma & Biotech